1-氯-3-[(4-甲基苯氧基)甲基]苯 | 6279-15-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-氯-3-[(4-甲基苯氧基)甲基]苯
• 英文名称: (3-chloro-benzyl)-p-tolyl ether
• 英文别名: (3-Chlor-benzyl)-p-tolyl-aether；1-Chloro-3-[(4-methylphenoxy)methyl]benzene
• CAS: 6279-15-8
• 化学式: C₁₄H₁₃ClO
• mdl: MFCD21365882
• 分子量: 232.71
• InChiKey: VYGXRWGMEIKQHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-氯甲苯 在 sodium hydroxide 、 磺酰氯 、 过氧化苯甲酰 作用下， 生成 1-氯-3-[(4-甲基苯氧基)甲基]苯
  参考文献：
  名称：

  Chloro Substituted Diphenylmethanes, Phenyl Benzyl Ethers and Benzophenones Prepared from Ortho- or Para-cresol^1,2

  摘要：

  DOI：

  10.1021/ja01150a022

文献信息

• 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors
  申请人：Ortho-McNeil-Janssen Pharmaceuticals, Inc.

  公开号：EP2426125A1

  公开（公告）日：2012-03-07

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是符合式 (I) 的新型吡啶酮衍生物 其中所有基团在申请和权利要求中均有定义。根据本发明的化合物是代谢受体-亚型 2（"mGluR2"）的正异位调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及涉及代谢受体的 mGluR2 亚型的疾病。特别是，这类疾病是选自焦虑症、精神分裂症、偏头痛、抑郁症和癫痫组的中枢神经系统疾病。本发明还涉及药物组合物和制备此类化合物及组合物的工艺，以及使用此类化合物预防和治疗涉及 mGluR2 的此类疾病。
• THERMOCHROMIC COLOR-MEMORY COMPOSITION AND THERMOCHROMIC COLOR-MEMORY MICROCAPSULE PIGMENT INCLUDING SAME
  申请人：THE PILOT INK CO., LTD.

  公开号：EP3192845A1

  公开（公告）日：2017-07-19

  [Problem] An object of the present invention is to provide: thermochromic color-memorizing composition which effectively expresses a property of being capable of interchangeably memorizing and retaining colors and is thus applicable to various fields; and thermochromic color-memorizing microcapsule pigment encapsulating the same. [Means for Solution] Provided are thermochromic color-memorizing composition and thermochromic color-memorizing microcapsule pigment encapsulating the same, the thermochromic color-memorizing composition including: (a) an electron-donating color-developing organic compound; (b) an electron-accepting compound; and (c) an ester compound represented by the following formula (1) as a reaction medium which controls color reaction between the components (a) and (b): (wherein, R represents an alkyl group having 4 to 22 carbon atoms, an alkenyl group having 4 to 22 carbon atoms, a cycloalkylalkyl group having 6 to 11 carbon atoms or a cycloalkyl group having 5 to 7 carbon atoms; X represents a hydrogen atom, an alkyl group, an alkoxy group or a halogen atom; Y represents a hydrogen atom, an alkyl group, an alkoxy group or a halogen atom; and n represents 0 or 1).

  [问题]本发明的目的是提供：热致变色颜色记忆组合物，该组合物有效地表达了能够互换记忆和保留颜色的特性，因此适用于各种领域；以及封装该组合物的热致变色颜色记忆微胶囊颜料。 [解决方法]本发明提供了热致变色颜色记忆组合物和封装该组合物的热致变色颜色记忆微胶囊颜料，热致变色颜色记忆组合物包括：(a) 电子捐赠显色有机化合物；(b) 电子接受化合物；以及 (c) 由下式 (1) 表示的酯类化合物，作为反应介质，控制成分 (a) 和 (b) 之间的颜色反应： (其中，R 代表具有 4 至 22 个碳原子的烷基、具有 4 至 22 个碳原子的烯基、具有 6 至 11 个碳原子的环烷基或具有 5 至 7 个碳原子的环烷基；X 代表氢原子、烷基、烷氧基或卤素原子；Y 代表氢原子、烷基、烷氧基或卤素原子；n 代表 0 或 1）。
• [EN] OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF<br/>[FR] COMPOSÉ D'OXAZINO-QUINAZOLINE ET DE TYPE OXYZINO-QUINAZOLINE, SON PROCÉDÉ DE PRÉPARATION ET SES APPLICATIONS<br/>[ZH] 一种噁嗪并喹唑啉与噁嗪并喹啉类化合物及其制备方法和应用
  申请人：BEIJING SCITECH MQ PHARMACEUTICALS LTD

  公开号：WO2019170088A1

  公开（公告）日：2019-09-12

  本发明提供一种噁嗪并喹唑啉与噁嗪并喹啉类化合物及其制备方法和应用，具体涉及式(I)所示化合物、其异构体、水合物、溶剂化物、其药学上可接受的盐及其前药，其制备方法及其在制备作为激酶抑制剂的药物中的应用。
• 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS
  申请人：Imogai Hassan Julien

  公开号：US20100166655A1

  公开（公告）日：2010-07-01

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
• 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20140315903A1

  公开（公告）日：2014-10-23

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.